Myricx Bio Awarded Cancer Research Horizons Start-Up Achievement Recognition Award for 2025
August 20, 2025
- Translating N-myristoyltransferase (NMT) science into promising new targeted cancer biotherapeutics
- Demonstrated potential of inhibitors of NMT (NMTi) as a completely novel payload for antibody-drug conjugates (ADCs)
- Development of a pre-clinical NMTi-ADC pipeline with recent nomination of development candidate in lead program
- On track to become a clinical stage company in 2026
- Expanded leadership and R&D teams following its 2024 £90 million ($114 million) series A financing and move to dedicated facilities in London
London, UK, 11 July 2025 – Myricx Bio (‘Myricx’), a UK-based biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce that it has been awarded the Cancer Research Horizons Start-Up Achievement Recognition Award for 2025, which it received at a ceremony in London last night.
A spin out from Imperial College London and the Francis Crick Institute, Myricx was selected as the winner for its achievements over the past two years based on the identification of the potential of its proprietary inhibitors of N-myristoyltransferase (NMTi) as a novel payload class for ADCs. It has demonstrated that NMTi-ADCs achieve complete and durable tumour regressions, at well-tolerated doses, in multiple solid cancer models.
Based on its strong proof-of-concept data highlighting the significant potential of NMTi-ADCs and the urgent need for novel ADC payloads, in 2024 the Company closed a £90 million ($114 million) series A financing. This was the largest ever series A raise for a UK spin-out biotech, providing the resources to enable it to become a clinical stage company. Over the past 12 months Myricx has moved to dedicated facilities in London, expanded its leadership and R&D teams, and advanced its pipeline of first-in-class NMTi-ADC drug candidates. Most recently, the Company has nominated its lead development candidate and expects to enter human clinical trials in 2026.
Acknowledging the award Myricx Bio CEO Robin Carr said, “It is an honour for Myricx to receive this award as it recognises the world-class research excellence of our scientific founders and our dedicated team that have worked so hard since our foundation to turn our scientific discoveries into the exciting pipeline of cancer drug candidates that we have today. Myricx is a highly ambitious company on the cusp of becoming a clinical-stage oncology company, driven by innovative and proprietary ADC technologies that leverage NMT inhibition. This mechanism of action holds the promise of creating a revolutionary new class of therapeutics that has the potential to transform the therapeutic options for cancer patients, empowering them to lead healthier and more fulfilling lives.”
The Cancer Research Horizons Innovation and Entrepreneurship Awards, organised by Cancer Research Horizons (CRH), Cancer Research UK’s innovation arm, and sponsored by law firm Mewburn Ellis, celebrate researchers and companies translating cancer research into real-world patient impact.
The ‘Cancer Research Horizons Start-Up Achievement Recognition Award’ is one of four awards in a special recognition category that recognises outstanding contributions to the academic cancer entrepreneurial field.
-Ends-
Notes to Editors:
About Myricx Bio – www.myricxbio.com
Myricx Bio (“Myricx”) is a UK-based biotechnology company focused on the discovery and development of therapeutics for the treatment of patients with cancer. Myricx is a global leader of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibition of N-myristoyltransferase (NMT).
Myricx is a spin out from Imperial College London and the Francis Crick Institute. Investors include Abingworth, Brandon Capital Partners, British Patient Capital, Cancer Research Horizons, Eli Lilly, Novo Holdings and Sofinnova Partners.
About N-myristoyltransferase inhibition
N-myristoyltransferase (NMT) is an enzyme responsible for the addition of a specific lipid to multiple proteins that are crucial for cancer cell survival. Myricx is developing a pipeline of antibody-drug conjugates (ADCs) to address significant unmet needs in oncology, leveraging its NMT inhibitor (NMTi) payload chemistry platform. These ADCs have demonstrated exceptional preclinical efficacy and tolerability across multiple solid tumour-associated antigens and cancer cell types.
Follow us on LinkedIn
For further information please contact
At the Company
Robin Carr, CEO, Myricx Bio
info@myricxbio.com
Media Enquiries
Sue Charles, Charles Consultants
sue@charles-consultants.com
+44 (0)7986 7265
